David P. Southwell
David P. Southwell's purchase track record
David P. Southwell has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/18/2022 | TCRX | $90K | -12.9% | -20.1% | +0.9% |
| 9/8/2021 | TCRX | $96K | -26.2% | -54.4% | -5.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
PTC Therapeutics to Report Q3 2026 Earnings on Oct 29. PTC Therapeutics has announced it will release its third-quarter 2026 financial results on October 29, 2026. This upcoming report is the primary catalyst for the stock in the near term. The company's shares are currently trading below the average analyst price target, with the stock recently testing key support levels.
Transaction History
| RCKT | ▼ Sell | Other | 150,000 | $0 | 8/3/2026 | View on chart |
| RCKT | ▲ Buy | Grant | 22,862 | $0 | 6/18/2026 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 1/2/2026 | View on chart |
| PTCT | ▲ Buy | Option Exercise | 12,000 | $370K | 9/9/2025 | View on chart |
| PTCT | ▼ Sell | Open Market | 12,000 | $700K | 9/9/2025 | View on chart |
| RCKT | ▲ Buy | Grant | 30,000 | $0 | 6/18/2025 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 1/3/2025 | View on chart |
| PTCT | ▼ Sell | Gift | 1,650 | $0 | 5/8/2024 | View on chart |
| RCKT | ▼ Sell | Gift | 59,716 | $0 | 5/2/2024 | View on chart |
| RCKT | ▼ Sell | Gift | 113,124 | $0 | 5/2/2024 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 29,624 | $129K | 4/15/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 10,000 | $241K | 4/15/2024 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 70,000 | $304K | 4/12/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 59,716 | $1.4M | 4/12/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 10,284 | $259K | 4/12/2024 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 2/15/2024 | View on chart |
| PTCT | ▲ Buy | Option Exercise | 11,429 | $206K | 4/17/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 6,241 | $316K | 4/17/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 5,188 | $267K | 4/17/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 2,571 | $129K | 3/31/2023 | View on chart |
| PTCT | ▲ Buy | Option Exercise | 2,571 | $46K | 3/31/2023 | View on chart |
| PTCT | ▲ Buy | Option Exercise | 10,000 | $271K | 3/27/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 4,599 | $206K | 3/27/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 5,301 | $241K | 3/27/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 100 | $5K | 3/27/2023 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 1/5/2023 | View on chart |
| TCRX | ▲ Buy | Open Market | 15,000 | $54K | 5/18/2022 | View on chart |
| TCRX | ▲ Buy | Open Market | 10,000 | $35K | 5/18/2022 | View on chart |
| PTCT | ▲ Buy | Grant | 3,200 | $0 | 1/7/2022 | View on chart |
| TCRX | ▲ Buy | Option Exercise | 48,670 | $96K | 12/23/2021 | View on chart |
| TCRX | ▲ Buy | Open Market | 11,000 | $96K | 9/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial
Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.